Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo Controlled, Trial to Assess Safety and Efficacy of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) for the Treatment of Adults With Spinocerebellar Ataxia

NCT05490563 is registered in ClinicalTrials.gov with Seelos Therapeutics, Inc. as lead sponsor.

NCT NCT05490563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05490563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo Controlled, Trial to Assess Safety and Efficacy of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) for the Treatment of Adults With Spinocerebellar Ataxia
Lead sponsor
Seelos Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
June 3, 2022
Completion date
November 24, 2023
Enrollment
23 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

spinocerebellar ataxia type 3